BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,055 filers reported holding BAXTER INTL INC in Q2 2022. The put-call ratio across all filers is 1.57 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $126,196,899 | -13.8% | 3,343,850 | +4.1% | 1.23% | -9.9% |
| Q2 2023 | $146,391,114 | +10.9% | 3,213,150 | -1.3% | 1.36% | +6.1% |
| Q1 2023 | $132,058,493 | +2.2% | 3,255,880 | +28.4% | 1.29% | +1.6% |
| Q4 2022 | $129,273,427 | +72.1% | 2,536,265 | +81.9% | 1.27% | +57.1% |
| Q3 2022 | $75,095,000 | -9.8% | 1,394,265 | +7.6% | 0.81% | +0.6% |
| Q2 2022 | $83,226,000 | -1.3% | 1,295,745 | +19.2% | 0.80% | +8.2% |
| Q1 2022 | $84,293,000 | +9.6% | 1,087,095 | +21.3% | 0.74% | +12.0% |
| Q4 2021 | $76,899,000 | +101.5% | 895,845 | +88.8% | 0.66% | +91.0% |
| Q3 2021 | $38,159,000 | -54.2% | 474,440 | -60.2% | 0.35% | -81.5% |
| Q2 2015 | $83,392,000 | -1.8% | 1,192,510 | -3.8% | 1.87% | +1.6% |
| Q1 2015 | $84,938,000 | -8.2% | 1,239,963 | -1.8% | 1.84% | -10.3% |
| Q4 2014 | $92,497,000 | +1.2% | 1,262,074 | -0.9% | 2.05% | -1.8% |
| Q3 2014 | $91,424,000 | -1.4% | 1,273,854 | -0.7% | 2.09% | -1.1% |
| Q2 2014 | $92,722,000 | -1.2% | 1,282,474 | +0.5% | 2.11% | -3.6% |
| Q1 2014 | $93,858,000 | +3.4% | 1,275,603 | -2.2% | 2.19% | +5.9% |
| Q4 2013 | $90,737,000 | +6.2% | 1,304,618 | +0.3% | 2.07% | +1.5% |
| Q3 2013 | $85,448,000 | +11.0% | 1,300,788 | +17.1% | 2.04% | +11.1% |
| Q2 2013 | $76,977,000 | – | 1,111,252 | – | 1.84% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |